Welcome to our dedicated page for Bio-Techne news (Ticker: TECH), a resource for investors and traders seeking the latest updates and insights on Bio-Techne stock.
Bio-Techne Corporation reports news about its global life sciences business, which supplies reagents, analytical instruments and precision diagnostics for research, biopharmaceutical, biotechnology and clinical diagnostic customers. Company updates commonly cover financial results, cash dividends, investor conference presentations and demand trends across large pharma, emerging biotech and academic markets.
Product news centers on Bio-Techne's R&D Systems™, Bio-Techne Spatial™ and Bio-Techne Diagnostics™ portfolios. Recent recurring themes include spatial biology workflow additions for the COMET™ suite, SPYRE™ antibody panels and amplification kits, GMP-grade reagents for cell and gene therapy workflows, and the Ella cartridge-based immunoassay platform for translational research and clinical applications.
Bio-Techne Corporation (NASDAQ: TECH) announced the commercial launch of GMP-grade proteins from its new St. Paul, MN facility, focusing on large-scale production for cell and gene therapy workflows. This investment of $50 million enhances its capacity to meet the increasing demand driven by over 1300 ongoing clinical trials in cell therapy, marking a 43% increase from the previous year. The facility's state-of-the-art technology and scalability aim to ensure lot-to-lot consistency and patient safety in GMP manufacturing.
Summary not available.
Bio-Techne Corporation (NASDAQ: TECH) announced a quarterly dividend of $0.32 per share for Q3 2021, payable on November 26, 2021. Shareholders of record as of November 12, 2021 will receive this dividend. With approximately $931 million in net sales in fiscal 2021, Bio-Techne continues to support research and clinical diagnostics as a leading provider of innovative tools and bioactive reagents globally.
Bio-Techne Corporation (NASDAQ:TECH) reported first quarter FY2022 financial results, highlighting a 26% increase in net sales to $257.7 million, driven by 21% organic revenue growth. GAAP EPS rose to $1.69 from $0.83 last year, while adjusted EPS was $1.83, up from $1.43. The Protein Sciences segment experienced 28% growth, with organic growth of 26%. Diagnostic and Genomics segment sales grew 22%. Strong commercial execution was noted across all regions, with China seeing growth over 50%. The company remains optimistic about its Cell and Gene Therapy initiatives.
Bio-Techne Corporation (NASDAQ:TECH) announced the publication of significant clinical research by Exosome Diagnostics in Prostate Cancer and Prostatic Diseases. The study reveals that the ExoDx Prostate Intelliscore test can effectively distinguish between high-grade and low-grade prostate cancers, potentially reducing unnecessary biopsies by 23%. With an impressive negative predictive value of 90%, this test aids in making informed biopsy decisions, aligning with updated NCCN guidelines. Dr. Johan Skog emphasized its importance in reducing overdiagnosis risks, empowering patients and physicians alike.
Bio-Techne Corporation (NASDAQ: TECH) announced a conference call and webcast on November 2, 2021, at 8:00 a.m. CDT to discuss its first quarter 2022 financial results. Investors can access the call via dial-in or webcast. A recorded replay will be available from 11:00 a.m. CDT on the same day until 11:00 p.m. CST on December 2, 2021. Bio-Techne, known for developing high-quality reagents and diagnostic products, generated approximately $931 million in net sales in fiscal 2021 and employs around 2,700 staff globally.
Bio-Techne (NASDAQ: TECH) has launched ExCellerate™ iPSC Expansion Medium, designed for the expansion and maintenance of induced pluripotent stem cells (iPSCs). This new medium supports research and clinical applications in regenerative medicine, as it is animal component-free and includes essential growth factors for iPSC maintenance. It provides a consistent cell culture environment, allowing for reliable performance in generating homogeneous iPSCs. The launch signifies Bio-Techne's commitment to advancing innovative solutions for researchers in cell and gene therapies.
Bio-Techne and Carterra have announced a clinical research collaboration focused on analyzing COVID-19 variants, including the Delta variant. This partnership aims to develop a fast and effective assay for assessing immune responses to variants that may evade vaccines. Utilizing Carterra's LSA platform, the study will characterize over 40 variants, generating high-definition insights from patient serum samples. Bio-Techne generated approximately $931 million in net sales in fiscal 2021, positioning it as a key player in COVID-19 research and diagnostics.
Bio-Techne Corporation (NASDAQ: TECH) announced that its CEO, Chuck Kummeth, will present at the 2021 Virtual Wells Fargo Healthcare Conference on September 9, 2021, at 2:00 p.m. EDT. Investors can access a live webcast of the presentation on the company's Investor Relations website. Bio-Techne specializes in high-quality proteins and reagent solutions, generating approximately $931 million in net sales in fiscal 2021, with around 2,700 employees globally.
Bio-Techne Corporation (NASDAQ:TECH) reported strong Q4 FY2021 results with a 39% organic revenue increase, reaching $259.0 million. Full-year organic growth hit 22% to $931.0 million. The adjusted EPS rose to $1.87, compared to $1.00 last year, despite GAAP EPS dropping to $0.37 from $1.48 due to a non-operating loss on investments. The fourth quarter saw an adjusted operating margin of 38.5%, up from 31.1% a year prior, while operating cash flow reached a record $352 million. The company anticipates continued growth momentum into FY2022.